Physician profile
Mary E Thibert
NPI 1457507287
$1,429.84
in general payments reported to CMS, 2019-2025
15 companies · $67.65 in 2025
The $67.65 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $631 · 2022: $568 · 2023: $16.79 · 2024: $146 · 2025: $67.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $230.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $279.98 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $226.18 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $179.59 | 2021 | |
| Vifor Pharma, INC. | $134.07 | 2021-2022 | |
| Janssen Biotech, INC. | $122.39 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $91.30 | 2024-2025 | Entyvio |
| Alexion Pharmaceuticals, INC. | $78.07 | 2021-2023 | Ultomiris |
| Calliditas Therapeutics US INC. | $68.94 | 2022 | |
| Akebia Therapeutics INC | $57.76 | 2021 | |
| Aurinia Pharma U.S., INC. | $46.65 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $42.68 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $36.41 | 2021-2022 | |
| Glaxosmithkline, LLC. | $29.29 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $19.35 | 2021 | |
| Opko Pharmaceuticals, LLC | $17.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Thibert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.